Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Front Med (Lausanne) · 2017 · PMC5329017 · PMID 28293555

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The intent-to-treat analysis of OS in all studied patients showed a 1-month improvement that did not reach statistical significance; however, when adjusted to the sum of longest diameters of target lesions, a significant OS benefit was seen ( 55 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.